Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended October 31, 2012 (fiscal Q2 and first half of fiscal 2013). Financial amounts below are in U.S. dollars; statement amounts are in thousands unless otherwise noted. The company develops TumorGraft-based oncology services through Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS).
Financial performance and position
| Metric | Three months ended Oct. 31, 2012 | Six months ended Oct. 31, 2012 |
|---|---|---|
| Revenue | $1.458 million, down 16.7% year over year | $3.564 million, up 5.7% year over year |
| Operating loss | $1.916 million, versus $2.469 million | $3.516 million, versus $4.685 million |
| Net loss | $1.974 million, versus $2.349 million | $3.297 million, versus $4.387 million |
| Loss per share | $0.04 | $0.07 |
| Cash used in operating activities | Not provided for the quarter | $2.554 million, versus $3.291 million |
- Revenue mix: Q2 POS revenue was $459,000, down 22.2%; TOS revenue was $999,000, down 13.2%. First-half POS revenue rose 15.9% to $1.377 million; TOS was essentially flat at $2.187 million.
- Margins: Management reported Q2 POS gross margin of -20% (17% in the prior-year quarter) and TOS gross margin of 50% (unchanged). First-half margins were 0% for POS (25% prior year) and 46% for TOS (50% prior year). Gross margin calculated from consolidated statement revenue and service-cost lines was approximately 27.5% for Q2 and 29.1% for the first half, versus approximately 38.0% and 39.2%, respectively, in the comparable periods.
- Liquidity: Cash and cash equivalents were $2.161 million at October 31, down from $4.716 million at April 30. Working capital was negative by less than $100,000. Management stated cash on hand was adequate to fund operations at least through April 30, 2013.
- Debt and liabilities: The filing reports no off-balance-sheet debt or similar obligations and no interest-bearing debt balance. Total liabilities were $3.250 million, including $322,000 of warrant liability and $1.205 million of deferred revenue. The $8.159 million redeemable common-stock balance is temporary equity, not debt.
- Balance-sheet position: Total assets were $4.225 million; stockholders’ deficit was $7.184 million.
Changes versus prior comparable periods
- Q2 revenue declined despite higher POS activity: the company performed 43 TumorGraft implants versus 23 and completed 9 drug studies versus 4. Lower pricing, part of its strategy to broaden access and expand its Tumorbank and model offerings, offset higher volumes.
- First-half revenue increased, driven by POS drug studies (22 completed versus 5); TOS first-half revenue was unchanged.
- Operating and net losses narrowed in both the quarter and first half, helped by lower R&D and general and administrative costs. R&D expense fell 60% in Q2 and 50% for the first half; G&A fell 20% and 26%, respectively.
- Service costs increased relative to revenue, especially in POS, and reported margins weakened. Management attributed POS cost growth to higher activity and TOS first-half margin pressure to the transition of laboratory work in-house.
- Operating cash use improved by $737,000 year over year for the first half, but cash declined by $2.555 million during that period. No financing cash was raised in the first half of 2013.
Outlook, risks, contingencies, and unusual items
- Management plans to focus POS on core TumorGraft implants and drug studies, with future POS revenue expected to be driven by those products. It expects in-house laboratory operations to lower future service costs and support competitive pricing, while noting it is evaluating ways to expand lab capacity.
- The company was exploring additional financing. Management cautioned that capital may not be available on acceptable terms, if at all; debt financing could carry high interest and restrictive covenants, while equity financing could dilute shareholders or carry preferential rights.
- On November 30, 2012, after quarter-end, Cephalon exercised an option to pay a one-time $880,000 fee for one compound, instead of future milestones or royalties. Payment was due within 30 days of exercise and remained outstanding as of the filing. No Cephalon milestones had been achieved as of October 31.
- Warrant-liability remeasurement generated $233,000 of first-half non-cash income; Q2 remeasurement produced $52,000 of expense. The liability’s fair value fell from $555,000 at April 30 to $322,000 at October 31.
- Investors in the 2011 financing retain a conditional right to require redemption of 12,533,333 shares for $0.75 per share following specified events. Warrants also have exercise-price reset provisions. Potential registration-default penalties were not accrued because management did not consider payment probable; the filing cites potential penalties of $41,000 per 30-day period.
- The company disclosed ordinary-course legal matters but no material expected exposure, and stated there were no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether additional financing is secured and whether cash runway remains consistent with management’s estimate.
- Whether the $880,000 Cephalon payment was received, and the effect of forgoing potential future milestones and royalties for that compound.
- Whether increased POS volumes and lower pricing can produce sustainable positive margins, and whether TOS bookings recover after the prior-quarter booking shortfall.
- Progress and costs of the in-house laboratory transition, including capacity needs and the expected timing and scale of cost savings.
- Potential shareholder dilution or cash obligations associated with the redeemable shares, warrant reset terms, and registration-rights provisions.